EI
PCVX icon

EAM Investors’s Vaxcyte PCVX Stock Holding History

EAM Investors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-72,995
Closed -$8.34M – 329
2024
Q3 		$8.34M Buy
72,995
+36,473
+100% +$3.29M 1.25% 2
2024
Q2 		$2.76M Sell
36,522
-7,210
-16% -$491K 0.45% 120
2024
Q1 		$2.99M Buy
+43,732
New +$3.03M 0.47% 119
2023
Q4 		– Sell
-17,289
Closed -$881K – 346
2023
Q3 		$881K Sell
17,289
-43,265
-71% -$2.13M 0.17% 257
2023
Q2 		$3.02M Buy
60,554
+10,691
+21% +$507K 0.56% 51
2023
Q1 		$1.87M Sell
49,863
-14,962
-23% -$635K 0.37% 126
2022
Q4 		$3.11M Buy
+64,825
New +$2.54M 0.64% 33

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

EAM Investors's PCVX Position: Q4 2024 in Review

EAM Investors sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 72,995 shares — an estimated $8.34M sold.

EAM Investors first reported a position in PCVX in Q4 2022 and held it in 7 quarters. The position peaked at $8.34M in Q3 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • EAM Investors reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
  • EAM Investors sold 72,995 Vaxcyte shares in Q4 2024, an estimated $8.34M.
  • EAM Investors first reported a position in Vaxcyte in Q4 2022 and held it in 7 quarters.
  • EAM Investors's Vaxcyte position peaked at $8.34M in Q3 2024.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on EAM Investors's 13F filing for Q4 2024, filed 13 Feb 2025.